Navidea Biopharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Navidea Biopharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
3,067,067
1.88%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
1,694,430
1.04%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
571,658
0.35%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
548,580
0.34%
0
0.02%
12/31/2017
299,402
0.18%
-45,750
0.91%
06/28/2018
Vanguard Institutional Total Stock Market Index Fund
158,410
0.1%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
148,549
0.09%
0
0%
07/31/2018
Vanguard Balanced Index Fund
88,919
0.05%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
71,331
0.04%
0
0%
09/06/2018
58,724
0.04%
12,216
0.49%
06/28/2018
| Address |
4995 Bradenton Avenue
Dublin Ohio 43017
United States
|
|
Employees
|
- |
| Website |
http://www.navidea.com |
| Updated |
07/08/2019 |
| Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The company operates through the following segments: Diagnostics, Therapeutics, and Corporate. |
